Xiaomin Lou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaomin Lou has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Lin Wu
CAS Key Laboratory of Genome Sciences and Information, China Gastrointestinal Cancer Research Center, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
5 shared publications Ningzhi Xu
**Laboratory of Cell and Molecular Biology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 100021
5 shared publications- Siqi Liu
BGI Genomics, Shenzhen 518083, China
5 shared publications - Siqi Liu
CAS Key Laboratory of Genome Sciences and Information, China Gastrointestinal Cancer Research Center, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
5 shared publications Yingying Xie
From the ‡CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China, 100101
5 shared publicationsJu Zhang
From the ‡CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China, 100101
4 shared publications
Latest Publications
- Open Access
- 23 October 2019
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 816272
Protein profiling reveals the characteristic changes of complement cascade pathway in the tissues of gastric signet ring cell carcinoma
Signet ring cell carcinoma (SRCC) is a histological subtype of gastric cancer that has distinct features in cellular morphology, epidemiology and clinicopathology compared with adenocarcinomas (ACs). Lacking of systematically molecular overview to this disease made a slow progress in diagnosis and therapy for SRCC. In the present proteomics study, the gastric tissues were collected from tumor and adjacent regions including 14 SRCC and 34 AC cases, and laser capture microdissection (LCM) was employed to eradicate cellular heterogeneity of the tissues. Over 6,000 proteins were quantified through data independent acquisition (DIA) mass spectrometry (MS). The quantitative profiles of proteomes in tumor tissues, either AC or SRCC, were dramatically different from that in the corresponding adjacencies, whereas the SRCC proteomes appeared not distinguishable to the AC proteomes via hierarchical clustering. However, focusing on univariate analysis and pathway enrichment unrevealed that some proteins and pathways bared the differences between SRCC and ACs. Importantly, the abundance changes for a bulk of proteins involved in complement cascade were highly associated with SRCC but not so sensitive to the AC status. A hypothesis, therefore, was proposed that the complement cascade was evoked in the SRCC microenvironment upon infiltration, while the SRCC cells survived from the complement cytotoxicity by secreting negative regulators. Moreover, an attempt was made to seek appropriate cell model for gastric SRCC, through proteomic comparison of the 15 gastric cell lines and the gastric tumors. The prediction upon supervised classifier suggested none of these gastric cell lines qualified in mimic to SRCC.
- 23 October 2019
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 816272
Open AccessProtein profiling reveals the characteristic changes of complement cascade pathway in the tissues of gastric signet ring cell carcinoma
Signet ring cell carcinoma (SRCC) is a histological subtype of gastric cancer that has distinct features in cellular morphology, epidemiology and clinicopathology compared with adenocarcinomas (ACs). Lacking of systematically molecular overview to this disease made a slow progress in diagnosis and therapy for SRCC. In the present proteomics study, the gastric tissues were collected from tumor and adjacent regions including 14 SRCC and 34 AC cases, and laser capture microdissection (LCM) was employed to eradicate cellular heterogeneity of the tissues. Over 6,000 proteins were quantified through data independent acquisition (DIA) mass spectrometry (MS). The quantitative profiles of proteomes in tumor tissues, either AC or SRCC, were dramatically different from that in the corresponding adjacencies, whereas the SRCC proteomes appeared not distinguishable to the AC proteomes via hierarchical clustering. However, focusing on univariate analysis and pathway enrichment unrevealed that some proteins and pathways bared the differences between SRCC and ACs. Importantly, the abundance changes for a bulk of proteins involved in complement cascade were highly associated with SRCC but not so sensitive to the AC status. A hypothesis, therefore, was proposed that the complement cascade was evoked in the SRCC microenvironment upon infiltration, while the SRCC cells survived from the complement cytotoxicity by secreting negative regulators. Moreover, an attempt was made to seek appropriate cell model for gastric SRCC, through proteomic comparison of the 15 gastric cell lines and the gastric tumors. The prediction upon supervised classifier suggested none of these gastric cell lines qualified in mimic to SRCC.
- Open Access
- 1 November 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (11) , 3429
Fungal Immunomodulatory Protein from Nectria haematococca Suppresses Growth of Human Lung Adenocarcinoma by Inhibiting the PI3K/Akt Pathway
Lung cancer is a common disease that is associated with poor prognosis. Fungal immunomodulatory protein from Nectria haematococca (FIP-nha) has potential as a lung cancer therapeutic; as such, illuminating its anti-tumor mechanism is expected to facilitate novel treatment options. Here, we showed that FIP-nha affects lung adenocarcinoma growth ex vivo and in vivo. Comparative quantitative proteomics showed that FIP-nha negatively regulates PI3K/Akt signaling and induces cell cycle arrest, autophagy, and apoptosis. We further demonstrated that FIP-nha suppresses Akt phosphorylation, leading to upregulation of p21 and p27 and downregulation of cyclin B1, cyclin D1, CDK2, and CDK4 expression, ultimately resulting in G1/S and G2/M cell cycle arrest. Meanwhile, FIP-nha-induced PI3K/Akt downregulation promotes A549 apoptosis by increasing the expression ratio of Bax/Bcl-2 and c-PARP and autophagy by decreasing the phosphorylation of mTOR. Thus, we comprehensively revealed the anti-tumor mechanism of FIP-nha, which inhibits tumor growth by modulating PI3K/Akt-regulated cell cycle arrest, autophagy, and apoptosis, and provided the basis for further application of fungal immunomodulatory proteins, especially FIP-nha.
- 1 November 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (11) , 3429
Open AccessFungal Immunomodulatory Protein from Nectria haematococca Suppresses Growth of Human Lung Adenocarcinoma by Inhibiting the PI3K/Akt Pathway
Lung cancer is a common disease that is associated with poor prognosis. Fungal immunomodulatory protein from Nectria haematococca (FIP-nha) has potential as a lung cancer therapeutic; as such, illuminating its anti-tumor mechanism is expected to facilitate novel treatment options. Here, we showed that FIP-nha affects lung adenocarcinoma growth ex vivo and in vivo. Comparative quantitative proteomics showed that FIP-nha negatively regulates PI3K/Akt signaling and induces cell cycle arrest, autophagy, and apoptosis. We further demonstrated that FIP-nha suppresses Akt phosphorylation, leading to upregulation of p21 and p27 and downregulation of cyclin B1, cyclin D1, CDK2, and CDK4 expression, ultimately resulting in G1/S and G2/M cell cycle arrest. Meanwhile, FIP-nha-induced PI3K/Akt downregulation promotes A549 apoptosis by increasing the expression ratio of Bax/Bcl-2 and c-PARP and autophagy by decreasing the phosphorylation of mTOR. Thus, we comprehensively revealed the anti-tumor mechanism of FIP-nha, which inhibits tumor growth by modulating PI3K/Akt-regulated cell cycle arrest, autophagy, and apoptosis, and provided the basis for further application of fungal immunomodulatory proteins, especially FIP-nha.
- Open Access
- 1 July 2017
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 16 (7) , 1217-1232
Lowering Endogenous Cathepsin D Abundance Results in Reactive Oxygen Species Accumulation and Cell Senescence
- 1 July 2017
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 16 (7) , 1217-1232
Open AccessLowering Endogenous Cathepsin D Abundance Results in Reactive Oxygen Species Accumulation and Cell Senescence
- Open Access
- 17 May 2017
- Published by Springer Nature in Clinical Proteomics
- Vol. 14 (1) , 1-9
The serum protein responses to treatment with Xiaoke Pill and Glibenclamide in type 2 diabetes patients
The Xiaoke Pill containing Chinese herb extracts and Glibenclamide, is used in therapy for type 2 diabetes mellitus (T2DM), and is effective in reducing the risk of hypoglycemia and improving diabetes symptoms compared with Glibenclamide. We describe a quantitative proteomics project to measure the T2DM serum proteome response to the Xiaoke Pill and Glibenclamide. Based on a recently conducted 48-week clinical trial comparing the safety and efficacy of Glibenclamide (n = 400) and Xiaoke Pill (n = 400), after matching for age, sex, BMI, drug dose and whether hypoglycemia occurred, 32 patients were selected for the serum based proteomic analysis and divided into four groups (with/without hypoglycemia treated with Xiaoke Pill or Glibenclamide, n = 8 for each group). We screened the differential serum proteins related to treatments and the onset of hypoglycemia using the iTRAQ labeling quantitative proteomics technique. Baseline and follow-up samples were used. The quantitative proteomics experiments demonstrated that 25 and 21 proteins differed upon treatment with the Xiaoke Pill in patients without and with hypoglycemia, respectively, while 24 and 25 proteins differed upon treatment with Glibenclamide in patients without and with hypoglycemia, respectively. The overlap of different proteins between the patients with and without hypoglycemia given the same drug treatment was much greater than between the patients given different drug treatments. We conclude that the serum proteins response to the two different anti-diabetic drug treatments may serve as a sensitive biomarker for evaluation of the therapeutic effects and continue investigations into the mechanism.
- 17 May 2017
- Published by Springer Nature in Clinical Proteomics
- Vol. 14 (1) , 1-9
Open AccessThe serum protein responses to treatment with Xiaoke Pill and Glibenclamide in type 2 diabetes patients
The Xiaoke Pill containing Chinese herb extracts and Glibenclamide, is used in therapy for type 2 diabetes mellitus (T2DM), and is effective in reducing the risk of hypoglycemia and improving diabetes symptoms compared with Glibenclamide. We describe a quantitative proteomics project to measure the T2DM serum proteome response to the Xiaoke Pill and Glibenclamide. Based on a recently conducted 48-week clinical trial comparing the safety and efficacy of Glibenclamide (n = 400) and Xiaoke Pill (n = 400), after matching for age, sex, BMI, drug dose and whether hypoglycemia occurred, 32 patients were selected for the serum based proteomic analysis and divided into four groups (with/without hypoglycemia treated with Xiaoke Pill or Glibenclamide, n = 8 for each group). We screened the differential serum proteins related to treatments and the onset of hypoglycemia using the iTRAQ labeling quantitative proteomics technique. Baseline and follow-up samples were used. The quantitative proteomics experiments demonstrated that 25 and 21 proteins differed upon treatment with the Xiaoke Pill in patients without and with hypoglycemia, respectively, while 24 and 25 proteins differed upon treatment with Glibenclamide in patients without and with hypoglycemia, respectively. The overlap of different proteins between the patients with and without hypoglycemia given the same drug treatment was much greater than between the patients given different drug treatments. We conclude that the serum proteins response to the two different anti-diabetic drug treatments may serve as a sensitive biomarker for evaluation of the therapeutic effects and continue investigations into the mechanism.
- 14 June 2016
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 15 (7) , 2164-2177
A Comprehensive Investigation toward the Indicative Proteins of Bladder Cancer in Urine: From Surveying Cell Secretomes to Verifying Urine Proteins
Urine is an ideal material to study the cancer-related protein biomarkers in bladder, whereas exploration to these candidates is confronting technique challenges. Herein, we propose a comprehensive strategy of searching the urine proteins related with bladder cancer. The strategy consists of three core combinations, screening the biomarker candidates in the secreted proteins derived from the bladder cancer cell lines and verifying them in patient urines, defining the differential proteins through two-dimensional electrophoresis (2DE) and isobaric tags for relative and absolute quantitation (iTRAQ) coupled with LC–MS/MS, and implementing quantitative proteomics of profiling and targeting analysis. With proteomic survey, a total of 700 proteins were found with their abundance of secreted proteins in cancer cell lines different from normal, while 87 proteins were identified in the urine samples. The multiple reaction monitoring (MRM)-based quantification was adapted in verifying the bladder cancer related proteins in individual urine samples, resulting in 10 differential urine proteins linked with the cancer. Of these candidates, receiver operating characteristic analysis revealed that the combination of CO3 and LDHB was more sensitive as the cancer indicator than other groups. The discovery of the bladder cancer indicators through our strategy has paved an avenue to further biomarker validation.
- 14 June 2016
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 15 (7) , 2164-2177
A Comprehensive Investigation toward the Indicative Proteins of Bladder Cancer in Urine: From Surveying Cell Secretomes to Verifying Urine Proteins
Urine is an ideal material to study the cancer-related protein biomarkers in bladder, whereas exploration to these candidates is confronting technique challenges. Herein, we propose a comprehensive strategy of searching the urine proteins related with bladder cancer. The strategy consists of three core combinations, screening the biomarker candidates in the secreted proteins derived from the bladder cancer cell lines and verifying them in patient urines, defining the differential proteins through two-dimensional electrophoresis (2DE) and isobaric tags for relative and absolute quantitation (iTRAQ) coupled with LC–MS/MS, and implementing quantitative proteomics of profiling and targeting analysis. With proteomic survey, a total of 700 proteins were found with their abundance of secreted proteins in cancer cell lines different from normal, while 87 proteins were identified in the urine samples. The multiple reaction monitoring (MRM)-based quantification was adapted in verifying the bladder cancer related proteins in individual urine samples, resulting in 10 differential urine proteins linked with the cancer. Of these candidates, receiver operating characteristic analysis revealed that the combination of CO3 and LDHB was more sensitive as the cancer indicator than other groups. The discovery of the bladder cancer indicators through our strategy has paved an avenue to further biomarker validation.
- 1 June 2016
- Published by Elsevier in Journal of Proteomics
- Vol. 141, 77-84
Nuclear phosphoproteomics analysis reveals that CDK1/2 are involved in EGF-regulated constitutive pre-mRNA splicing in MDA-MB-468 cells
- 1 June 2016
- Published by Elsevier in Journal of Proteomics
- Vol. 141, 77-84
Nuclear phosphoproteomics analysis reveals that CDK1/2 are involved in EGF-regulated constitutive pre-mRNA splicing in MDA-MB-468 cells
- Open Access
- 11 April 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (22) , 32592-32606
The levels of serine proteases in colon tissue interstitial fluid and serum serve as an indicator of colorectal cancer progression
The levels of serine proteases in colon tissue interstitial fluid and serum serve as an indicator of colorectal cancer progression
- 11 April 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (22) , 32592-32606
Open AccessThe levels of serine proteases in colon tissue interstitial fluid and serum serve as an indicator of colorectal cancer progression
The levels of serine proteases in colon tissue interstitial fluid and serum serve as an indicator of colorectal cancer progression
- 1 March 2016
- Published by Elsevier in Journal of Proteomics
- Vol. 136, 13-24
mTORC1 alters the expression of glycolytic genes by regulating KPNA2 abundances
- 1 March 2016
- Published by Elsevier in Journal of Proteomics
- Vol. 136, 13-24
mTORC1 alters the expression of glycolytic genes by regulating KPNA2 abundances
- 8 September 2015
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 14 (10) , 4319-4331
A Comprehensive Proteomics Analysis Reveals a Secretory Path- and Status-Dependent Signature of Exosomes Released from Tumor-Associated Macrophages
Exosomes are 30–120 nm-sized membrane vesicles of endocytic origin that are released into the extracellular environment and play roles in cell–cell communication. Tumor-associated macrophages (TAMs) are important constituents of the tumor microenvironment; thus, it is critical to study the features and complex biological functions of TAM-derived exosomes. Here, we constructed a TAM cell model from a mouse macrophage cell line, Ana-1, and performed comparative proteomics on exosomes, exosome-free media, and cells between TAMs and Ana-1. Proteomic analysis between exosome and exosome-free fractions indicated that the functions of exosome dominant proteins were mainly enriched in RNA processing and proteolysis. TAM status dramatically affected the abundances of 20S proteasome subunits and ribosomal proteins in their exosomes. The 20S proteasome activity assay strongly indicated that TAM exosomes possessed higher proteolytic activity. In addition, Ana-1- and TAM-derived exosomes have different RNA profiles, which may result from differential RNA processing proteins. Taken together, our comprehensive proteomics study provides novel views for understanding the complicated roles of macrophage-derived exosomes in the tumor microenvironment.
- 8 September 2015
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 14 (10) , 4319-4331
A Comprehensive Proteomics Analysis Reveals a Secretory Path- and Status-Dependent Signature of Exosomes Released from Tumor-Associated Macrophages
Exosomes are 30–120 nm-sized membrane vesicles of endocytic origin that are released into the extracellular environment and play roles in cell–cell communication. Tumor-associated macrophages (TAMs) are important constituents of the tumor microenvironment; thus, it is critical to study the features and complex biological functions of TAM-derived exosomes. Here, we constructed a TAM cell model from a mouse macrophage cell line, Ana-1, and performed comparative proteomics on exosomes, exosome-free media, and cells between TAMs and Ana-1. Proteomic analysis between exosome and exosome-free fractions indicated that the functions of exosome dominant proteins were mainly enriched in RNA processing and proteolysis. TAM status dramatically affected the abundances of 20S proteasome subunits and ribosomal proteins in their exosomes. The 20S proteasome activity assay strongly indicated that TAM exosomes possessed higher proteolytic activity. In addition, Ana-1- and TAM-derived exosomes have different RNA profiles, which may result from differential RNA processing proteins. Taken together, our comprehensive proteomics study provides novel views for understanding the complicated roles of macrophage-derived exosomes in the tumor microenvironment.